One victory for biopharma over the coronavirus in 2020
A rollercoaster year for biopharma ended with investors firmly deciding that the pandemic was an opportunity, not a threat.
A tale of two Covids for smaller device makers
The pandemic provided the best and worst of times for smid-cap medtechs.
Covid or not, venture financing breaks records
Private biotechs attracted more venture cash in 2020 than in any other year of the current cycle.
Telemedicine and the “Zoom effect” boost big-cap medtech
In the second half of 2020 medtech began a tentative – and possibly short-lived – recovery.
Astrazeneca shows megamergers were still possible in 2020
One of the biggest surprises of 2020 was how biopharma M&A emerged relatively unscathed from Covid-19.
Drug rejections rise as Covid-19 bites
Alkermes manages to shrug off yesterday’s complete response letter, but US knockbacks in 2020 are creeping up.
Corporate investing plays an ever bigger role in medtech
The newest player in corporate financing, Intuitive, intends to deploy its fund with surgical precision.
Biopharma buyouts still pricey
A global pandemic has done nothing to crimp M&A premiums, with acquirers forced to swallow ever higher price tags.
Biopharma shares keep riding the Covid wave
The pandemic remains the dominant storyline for drug stocks at the nine-month mark, with Vertex and Horizon rare non-Covid-related risers.
